TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05158374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: 75mg Aspirin once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: 75mg Aspirin once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: 75mg Aspirin once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: 75mg Aspirin once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500mg Metformin once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500mg Metformin once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500mg Metformin once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500mg Metformin once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and Metformin
Description: 75mg Aspirin and 500mg Metformin once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and Metformin
Description: 75mg Aspirin and 500mg Metformin once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and Metformin
Description: 75mg Aspirin and 500mg Metformin once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and Metformin
Description: 75mg Aspirin and 500mg Metformin once per day
Study: NCT05916027

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The 15-Method
Description: The 15-Method is a Screening and Brief Intervention method for identifying and treating alcohol problems in primary care. The method combines evidence-based approaches from specialized addiction treatment with screening and readily available treatment options in general practice to help identify and treat alcohol problems. The 15-method is based on Motivational Interviewing, Cognitive Behavioral Therapy and utilizes the Alcohol Use Disorder Identification Test (AUDIT) as a screening tool. The 15-Method contains three flexible steps: Identification of clinical problem related to alcohol; feedback and clinical work-up as needed; treatment. Treatment includes structured consultations (maximum of four) with patient home-work assignments, and can be combined with pharmacological treatment for alcohol problems.
Study: NCT04349774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group - ESP block with SAP block
Description: None - Control Group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Group - ESP block with SAP normal saline
Description: Substitution of normal saline in place of 0.375% Bupivacaine in SAP block
Study: NCT05145907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TJ107 +Pembrolizumab
Description: TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV
Study: NCT05486351

Intervention type: OTHER
Intervention: Observation
Description: Patients are observed for stroke or systemic embolism and haemorrhagic transformation

Intervention type: OTHER
Intervention: Observation
Description: Patients are observed for stroke or systemic embolism and haemorrhagic transformation
Study: NCT06175884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video about pain neuroscience education with enhancing communication skills
Description: Participants will watch a brief video on pain neuroscience in which physiotherapist will show evidence-based communication skills to effectively convey information to patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video about pain neuroscience education without enhancing communication skills
Description: Participants will watch a brief video on pain neuroscience in which physiotherapist will not show evidence-based communication skills to effectively convey information to patients.
Study: NCT05003843

Intervention type: DEVICE
Group type: OTHER
Intervention: Indigo Aspiration System
Description: Indigo Aspiration System
Study: NCT05500794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBSR (Mindfulness-Based Stress Reduction)
Description: MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.~In each weekly session, the instructor creates a supportive environment in which:~* Guided meditation practices;~* Mindfulness stretching and yoga;~* Reflection and group discussion periods aimed at promoting mindfulness in daily life;~* Practice instructions and opportunity to ask questions;~* Instructions for home practice. Audio recordings and a manual are provided to support personal practice.~Audio recordings and a manual are provided to support personal practice
Study: NCT06603519

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Plant-Based Mediterranean Diet
Description: Two-week dietary intervention after the participants' scheduled colonoscopy consisting of vegetarian high-fiber meals. These meals are designed to provide a substantial intake of dietary fiber through a variety of plant-based foods, including whole grains, legumes, fruits, vegetables, nuts, and seeds. Meals will be delivered bi-weekly, and compliance will be monitored through regular check-ins with a study dietitian.
Study: NCT06654427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obstetric Trauma Informed Care Toolkit
Description: The OB-TIC toolkit will include provider and staff training on trauma- informed care and information on trauma-related perinatal concerns; trauma assessment tools; trauma-informed procedure modifications; clinical language guides; patient-facing resources including birth strategies, referral resources, and education; and clinical language. The OB-TIC intervention will utilize the toolkit to integrate trauma-informed care into clinical practice. Implementation strategies will be assessed to determine the most effective method for integrating OB-TIC content into practice.
Study: NCT06654219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged fasting
Description: NPO for solids: 24 hours prior to procedure, clear liquid diet (CLD) for 24 hours with last intake of clears no less than 2 hours prior to a procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard NPO
Description: NPO after midnight prior to procedure; Minimum solid fasting duration of 8 hours for solids and 2 hours for liquids
Study: NCT06654453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Manual thrombectomy followed by Percutaneous Coronary Intervention (PCI), a procedure involving mechanical removal of thrombus before stent placement in coronary arteries to restore blood flow in STEM

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention, involving balloon angioplasty and stent placement to open blocked coronary arteries in STEMI patients after thrombolysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention, involving balloon angioplasty and stent placement to open blocked coronary arteries in STEMI patients after thrombolysis.
Study: NCT06609577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diaphragm Ultrasound-Guided External Diaphragm Pacing
Description: This intervention, Diaphragm Ultrasound-Guided External Diaphragm Pacing (DU-EDP), is distinguished by its personalized approach, where diaphragm pacing is dynamically adjusted based on real-time diaphragm function measurements obtained through bedside diaphragm ultrasound (DU). Unlike standard external diaphragm pacing (EDP) interventions that use uniform pacing parameters, DU-EDP allows for the customization of pacing intensity, frequency, and duration for each patient. This intervention specifically integrates novel diaphragm function indices, such as diaphragm thickening fraction (DTF) and diaphragmatic rapid shallow breathing index (D-RSBI), to enhance precision in weaning from mechanical ventilation. The combination of these advanced metrics with real-time ultrasound guidance makes DU-EDP a highly individualized and innovative intervention for critically ill, mechanically ventilated patients.
Study: NCT06591403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the index and middle fingers of each participant&amp;#39;s active hand
Description: A pulse oximeter was placed simultaneously on the index and middle fingers of each participants active hand while they were in an upright sitting position. After the pulse oximeter was placed on both fingers for one minute, stable values seen on its screen for at least three seconds were recorded. Then, the participants were placed in a supine position, and after a 10-minute rest, similar measurements were repeated with a pulse oximeter placed on the index and middle fingers of the active hand.
Study: NCT06596681

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GA+clozapine
Description: Patients were first given intracranial injections of GA and observed for 14-28 days, followed by a dose-climbing trial of clozapine medication, and finally, after the investigators had determined an effective dose of clozapine, the patients were given a fixed dose of clozapine orally for three months.
Study: NCT06590415

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous adipose tissue biopsy
Description: Under local anesthesia, subcutaneous adipose tissue will be collected from 2 puncture points in the umbilical region for a total volume of 2 mL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue biopsy
Description: Under local anesthesia, subcutaneous adipose tissue will be collected from 2 puncture points in the umbilical region for a total volume of 2 mL.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: One 4 mL tube of blood will be collected

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: One 4 mL tube of blood will be collected
Study: NCT06615349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DigiPall
Description: DigiPall is an intervention combining a sensor-equipped wearable with a chatbot communicating via WhatsApp on the patient's smartphone. Patients will be asked two questions daily for their subjective rating through WhatsApp on their smartphone, worded slightly differently depending on the measured values for steps, heart rate and compliance as well as the patient's answer the day before.
Study: NCT06591338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Study: NCT06042205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TISSIUM™ Atraumatic Hernia Repair System (TAHRS)
Description: The TAHRS is intended for fixation of prosthetic material to soft tissue
Study: NCT06587373

Intervention type: OTHER
Intervention: Assessment of the quality of mother-child dyadic relationships
Description: Filling out questionnaires

Intervention type: OTHER
Intervention: Assessment of the quality of mother-child dyadic relationships
Description: Filling out questionnaires
Study: NCT06112509

Intervention type: OTHER
Group type: OTHER
Intervention: Vestibular exam
Description: Interrogation, videonystagmoscopy, videonystagmography, video-head-impulse-test
Study: NCT06383273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MELT-300 sublingual tablet
Description: Each dose of MELT-300 will be provided as a single sublingual tablet, containing 3 mg midazolam and 50 mg ketamine. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midalozam sublingual tablet
Description: Each dose of midazolam will be provided as a single sublingual tablet, containing 3 mg midazolam. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sublingual tablet
Description: Each dose of placebo will be provided as a matching sublingual tablet, containing placebo. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
Study: NCT05480748

Intervention type: DEVICE
Intervention: monitoring
Description: ORI warning time, SpO2 warning time, added time were recorded.

Intervention type: DEVICE
Intervention: monitoring
Description: ORI warning time, SpO2 warning time, added time were recorded.
Study: NCT04938583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg).~2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/Kg Day 1 (every 21 days) until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2, Day 1 x 6 cycles (every 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 IV Day 1 x 6 cycles (every 21 days)
Study: NCT04840108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Person Coaching Intervention
Description: The intervention condition will include, for the SPs, a manualized, 1-session coaching intervention delivered by a research coach. The call will be delivered by phone using VA-permitted remote audio or video communication technology (e.g., doximity dialer, Zoom, or VA Video Connect if a Veteran). Coaches will use behavior change strategies delivered with a MI style.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Person Written Materials
Description: Support persons will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Person Written Materials
Description: Support persons will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail.
Study: NCT04445571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thin catheter technique or standard ET-tube for surfactant administration
Description: Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thin catheter technique or standard ET-tube for surfactant administration
Description: Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.
Study: NCT04353180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment
Description: After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment
Description: Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin (13 cis retinoic acid ) capsules
Description: 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized 13 cis retinoic acid
Description: Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study: NCT05047809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jingchuang Ointment(JCO)
Description: Applied once a day on the wounds

Intervention type: OTHER
Group type: OTHER
Intervention: Regular Treatment
Description: Do not use the Jingchuang Ointment(JCO), as the regular treatment as usual.
Study: NCT06503172

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Taiwanese whole grain job's tear (red job's tear)
Description: 300cc drink made from red job's tear, 2 bottle/day from week 0 to week 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Taiwanese whole grain job's tear (red job's tear)
Description: 300cc drink made from red job's tear, 2 bottle/day from week 0 to week 8

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: White job's tear
Description: 300cc drink made from white job's tear, 2 bottle/day from week 0 to week 8

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: White job's tear
Description: 300cc drink made from white job's tear, 2 bottle/day from week 0 to week 8
Study: NCT05941078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICF-based post-stroke rehabilitation program
Description: Patients completed an intake interview with a case therapist for an initial assessment and setting of personal treatment goals. The therapist assisted the patient with setting goals that were related to their life roles and functional gaps in terms of body function and activity and participation. Patients' personalized treatment plans were composed in case conferences. The treatment program contents were organized as ICF-based body function and activity and participation intervention modules. Each of the occupational therapy, physiotherapy, and speech therapy disciplines set the aims and developed the training contents, intensities, durations, and upgrading and completion criteria.
Study: NCT05394064

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SBT101
Description: SBT101 Treatment

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Imitation Procedure
Description: Procedure that mimics SBT101 infusion, but contains no drug administered
Study: NCT06539910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: All blocks will be performed after induction of general anaesthesia (GA). Upon arrival to the operating room (OR), a multichannel monitor will be attached to patients, followed by the administration of 2 mg midazolam IV after securing an IV cannula. Controlled GA via a laryngeal mask airway (LMA) will be done to all patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: All blocks will be performed after induction of general anaesthesia (GA). Upon arrival to the operating room (OR), a multichannel monitor will be attached to patients, followed by the administration of 2 mg midazolam IV after securing an IV cannula. Controlled GA via a laryngeal mask airway (LMA) will be done to all patients
Study: NCT05992922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC265 Ophthalmic Solution 1%
Description: 1 drop will be instilled in each eye twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution (Vehicle)
Description: 1 drop will be instilled in each eye twice a day
Study: NCT05447884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A zero impedance mode, controlling a wearable bilateral hip exoskeleton
Description: The bilateral hip exoskeleton has two degrees of freedom to enable the hip joint extension and flexion movement on both left and right sides. The zero impedance mode will not provide any assistance or resistance to the hip joints.
Study: NCT04807842

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: vaginal gel
Description: The placebo gel is a non-buffered gel. The active device is an acidic gel.
Study: NCT04897828

Intervention type: DEVICE
Intervention: Covered Stent placement
Description: Covered stent placement for the treatment of dysfunctional vascular access of hemodialysis patients
Study: NCT05447884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A zero impedance mode, controlling a wearable bilateral hip exoskeleton
Description: The bilateral hip exoskeleton has two degrees of freedom to enable the hip joint extension and flexion movement on both left and right sides. The zero impedance mode will not provide any assistance or resistance to the hip joints.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton
Description: The personalized optimal assistance mode includes both individualized hip flexion and hip extension assistance, which is determined by using the reinforcement learning-based automatic control parameters tuning during walking tasks. Therefore, the personalized optimal assistance will be able to improve the walking gait performance and reduce the energetic consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton
Description: The personalized optimal assistance mode includes both individualized hip flexion and hip extension assistance, which is determined by using the reinforcement learning-based automatic control parameters tuning during walking tasks. Therefore, the personalized optimal assistance will be able to improve the walking gait performance and reduce the energetic consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A free walking mode, without wearing a wearable bilateral hip exoskeleton
Description: The free walking mode will not include the usage of the wearable bilateral hip exoskeleton, and the human walking subjects will conduct pure natural walking tasks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A free walking mode, without wearing a wearable bilateral hip exoskeleton
Description: The free walking mode will not include the usage of the wearable bilateral hip exoskeleton, and the human walking subjects will conduct pure natural walking tasks.